Friday, 27 Mar 2020

You are here

Hospitalizations Decline for Rheumatoid Arthritis, But Increase in Gout

JAMA has reported the results of an 18-year National Inpatient Sample, a database of US non-federal hospitalizations. They examined the rate of hospitalizations for gout and rheumatoid arthritis (RA) and demonstrated a steady decline in RA, but a growing number of gout hospitalizations.

There were 254,982 hospitalizations for gout and 323,649 hospitalizations for RA between 1993 and 2011.

During this period, the hospitalization rate for RA went down from 13.9 to 4.6 per 100 000 adults (P < .001). At the same time, gout hospitalizatins increased from 4.4 to 8.8  per 100,000 adults. During this same era, the prevalence of RA dropped from 2.5 to 1.3 million affected Americans and the growth of gout (to current 8.3 million) has been fueled by the obesity epidemic. 

The authors believe these findings may reflect suboptimal care received by gout patients and its increasing prevalence, while at the same time pointing to the success of earlier diagnosis and more aggressive therapies in RA.

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Rheumatologists' Comments

Looks like the same is shown for Canada. Arthritis Care Res 2016 Aug 26. Trends in Gout and Rheumatoid Arthritis Hospitalizations in Canada from 2000-2011...indings indicate that hospitalization rates for gout have doubled over the past decade, while those for RA have decreased considerably. While these data provide an encouraging benchmark for RA care, they also highlight the critical need to improve gout management and prevention to mitigate its rising disease burden in Canada and beyond.

More Like This

Interleukin-37 Targeting in Gout

The Annals of Rheumatic Disease reports that interleukin- 27 (IL-37) may play an important role in the pathogenesis of gout, paving the way for future therapy with recombinant IL-37 in gouty arthritis.

Activation of the inflammasome by monosodium urate crystals is thought to be paramount to the innate immune response that drives IL-1-mediated joint inflammation in gout.

Hyperuricemia Predisposes to Coronary Artery Disease in Men

There are numerous associations between hyperuricemia and cardiovascular disease (CVD). An analysis of the Swedish SCAPIS Pilot study shows that higher levels of serum urate (SU) are associated with an increase in coronary artery calcification score in men but not in women. SU is not associated with common carotid intima-media thickness and carotid plaque scores in either men or women.

Hypersensitivity Reactions and Gout Tx: Watch the Dose

Both allopurinol and febuxostat (Uloric) were associated with an increased risk of hypersensitivity reactions among new users of these urate-lowering therapies, a large U.S. study found.

Diabetics using SGLT2 Inhibitors have a lower Gout Risk

Researchers from the Brigham and Women's Hospital have reported that adults with type 2 diabetes who were treated with SGLT2 inhibitors had a lower risk of gout compared to GLP1 agonist, suggesting that sodium–glucose cotransporter-2 inhibitors may reduce the risk for gout with type 2 diabetes mellitus (T2DM).

A Role for SGLT2 Inhibition in Gout?

The antidiabetic medication canagliflozin (Invokana) lowered serum urate and reduced the risk of gout flare in a post-hoc analysis of data from two large clinical trials.